曲美他嗪对急性心肌梗死择期PCI患者BNP水平的影响

Effects of trimetazidine on BNP of AMI undergoing elective PCI

目的:研究曲美他嗪对择期经皮冠状动脉介入治疗(PCI)急性心肌梗死(AMI)患者术后B型脑钠肽(BNP)水平的影响。方法:AMI在发病2周后接受PCI治疗的患者60例,随机分为曲美他嗪(TMZ)组(30例)及对照组(30例),两组患者均接受冠心病二级预防治疗,TMZ组于介入前即刻给予TMZ 60 mg顿服;之后TMZ 20mg,3次/d。对照组不给予TMZ。观察两组患者PCI术前、术后24h、6个月的BNP水平。结果:PCI术后24h及6个月TMZ组患者BNP水平低于对照组,两组之间差异有统计学意义(P<0.05)。结论:TMZ可降低择期PCI的AMI患者BNP水平,可使AMI患者进一步获益。

Objective： To investigate the effects of trimetazidine on BNP of acute myocardial infarction （AMI） patients undergoing elective PCI. Methods： Sixty patients with AMI undergoing PCI in two weeks after onset were enrolled. All patients were randomly divided into trimetazidine-treated group （30 cases） and control group （30 cases）. The patients in the two groups were all received the coronary secondary prevention. The trimetazidine-treated group added trimetazidine 60mg before PCI, followed by 20mg 3 times daily. The serum levels of BNP in both two groups were measured before PCI, 24h and 6 months after PCI. Results： The serum level of BNP in trimetazidine-treated group was significantly lower than that in control group at 24h and 6 months after PCI （P〈0.05）. Conclusion： Trimetazidine can decrease the serum level of BNP in AMI patients with elective PCI. Such patients can gain further benefit by combining with application of trimetazidine.